samrotamab vedotin (ABBV-085) / AbbVie  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
samrotamab vedotin (ABBV-085) / AbbVie
NCT02565758: ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Completed
1
85
US, Europe
ABBV-085
AbbVie
Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Carcinoma of the Breast
03/19
03/19

Download Options